190A.T
Chordia Therapeutics Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 50.00
−1.96%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Expenses | |||
| R&D Expense | — | — | — |
| SG&A Expense | — | — | — |
| General & Admin Expense | — | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | — | — | — |
| Cost and Expenses | — | — | — |
| Operating Income (EBIT) | (1.5B) | (1.8B) | (1.8B) |
| Non-Operating | |||
| Interest Income | — | — | — |
| Interest Expense | — | — | — |
| Net Interest Income | — | — | — |
| Other Non-Op Income/Expense | 23.0M | 20.1M | (23.3M) |
| Non-Operating Income (excl Interest) | 876.0K | 918.0K | 104.0K |
| EBT (Pre-Tax Income) | (1.5B) | (1.8B) | (1.8B) |
| Income Tax Expense | 2.3M | 2.4M | 2.4M |
| Bottom Line | |||
| Net Income | (1.5B) | (1.8B) | (1.8B) |
| Earnings from Cont. Ops | — | — | — |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (1.5B) | (1.8B) | (1.8B) |
| Per Share | |||
| Basic EPS | (¥21) | (¥26) | (¥31) |
| Diluted EPS | (¥21) | — | — |
| Revenue Per Share | — | — | — |
| Shares | |||
| Basic Shares Outstanding | 69.7M | 68.6M | 58.7M |
| Diluted Shares Outstanding | — | — | — |
| Profitability Metrics | |||
| EBITDA | (738.3M) | (1.8B) | (1.8B) |
| D&A | 2.7M | 2.7M | 4.1M |
| EBIT | (1.5B) | (1.8B) | (1.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Feb 1, 2026